When we correlate the levels of cystatin C and β2M in patients who after the third cycle of therapy experienced partial or complete remission, result is more pronounced correlation in the total sample of patients, in the group of aggressive lymphomas, and in the subgroup of aggressive nodal lymphoma (Table 2). This evidence concerns the gene CST3 and lymphoma.